Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD

UnknownOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Methylphenidate (MPH)

Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.

DRUG

Atomoxetine

Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.

Trial Locations (1)

RECRUITING

Asan Medical Center, Seoul